GABAvsUridine

GABA binds to GABA-A receptors (ligand-gated Cl- channels with alpha1-6, beta1-3, gamma1-3 subunits) and GABA-B receptors (G-protein coupled, Gi/o mediated), reducing neuronal excitability through hyperpolarization. However, supplemental GABA has limited blood-brain barrier penetration due to absence of a dedicated transporter and rapid metabolism by GABA-transaminase and succinate semialdehyde dehydrogenase in periphery. The calming effects may be mediated through: (1) GABA-A and GABA-B receptors in the enteric nervous system (gut-brain axis) — vagal afferents project to the nucleus tractus solitarius and influence limbic regions; (2) small amounts crossing the BBB via paracellular leakage or in individuals with compromised barrier integrity; (3) peripheral effects reducing systemic stress markers (cortisol, heart rate variability). PharmaGABA (Lactobacillus fermentation product) may have better absorption via peptide-like transport or different pharmacokinetics.

Uridine (as UMP) is phosphorylated to UTP and enters the Kennedy pathway, where it combines with choline via CTP:phosphocholine cytidylyltransferase to form CDP-choline — the rate-limiting step in phosphatidylcholine synthesis. Uridine provides the nucleotide component needed for constructing phosphatidylcholine in neuronal cell membranes and synaptic vesicles. Uridine stimulates neurite outgrowth and synaptogenesis via activation of P2Y receptors and downstream PI3K/Akt signaling. It upregulates dopamine D2 receptor expression in the striatum and enhances dopaminergic neurotransmission. When combined with DHA (from fish oil) and choline, the three compounds synergistically increase synaptic membrane synthesis, dendritic spine density, and dopaminergic signaling — the 'Mr. Happy Stack' mechanism.